EPS for Iovance Biotherapeutics, Inc. (IOVA) Expected At $-0.28

Analysts expect Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) to report $-0.28 EPS on May, 9.They anticipate $0.03 EPS change or 9.68 % from last quarter’s $-0.31 EPS. After having $-0.27 EPS previously, Iovance Biotherapeutics, Inc.’s analysts see 3.70 % EPS growth. The stock decreased 4.13% or $0.48 during the last trading session, reaching $11.15. About 761,714 shares traded. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has declined 37.96% since April 16, 2018 and is downtrending. It has underperformed by 42.33% the S&P500.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company has market cap of $1.38 billion. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes , which are T cells derived from patients' tumors for the treatment of patients with refractory metastatic melanoma. It currently has negative earnings. It is also developing LN-145 to treat cervical and head and neck cancers.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

More notable recent Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) news were published by: Seekingalpha.com which released: “Iova Biotherapeutics: Analysts Grow Positive – Seeking Alpha” on July 15, 2018, also Globenewswire.com with their article: “Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update – GlobeNewswire” published on February 27, 2019, Globenewswire.com published: “Iovance Biotherapeutics and MaSTherCell Announce New Manufacturing Services Agreement in Europe – GlobeNewswire” on October 18, 2018. More interesting news about Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) were released by: Globenewswire.com and their article: “Iovance Biotherapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference – GlobeNewswire” published on December 21, 2018 as well as Seekingalpha.com‘s news article titled: “Zynerba Rockets Forward – Seeking Alpha” with publication date: April 08, 2019.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Ratings Chart